The Motley Fool··Eric VolkmanLegend Biotech Surges 18% on Bullish Analyst Calls and Sector M&A Momentum
Legend Biotech surges 18% on bullish analyst upgrades and momentum from Eli Lilly's $7B CAR-T acquisition, with CD19/CD20 therapy driving investor enthusiasm.
LLYLEGNacquisitionanalyst upgrade